The Association Between Peri-Operative Hyperglycemia and Major Morbidity and Mortality

• Sponsor: University of Medicine and Dentistry of New Jersey (Other)
• Overall Status: Terminated
• CT.gov ID: NCT00487162
• Collaborator: (none)
• Enrollment: 56
• Location: 1
• Arms: 2
• Duration (Months): 19.1
• Patients Per Site Per Month: 2.9

Study Details

Study Description

Brief Summary

Surgery induces a stress effect on the body partially through a catabolic energy state. In turn, glucose levels may rise to levels which have been associated with major morbidity (Golden, 1999) and mortality (Ouattara, 2005). An increasing body of evidence suggests that intensive insulin therapy for tight control of blood glucose levels in certain surgical and critical care patient populations may improve mortality and selected morbidity outcomes when compared to those patients receiving conventional insulin therapy and blood glucose management. More specifically, poor intra-operative blood glucose control is associated with worse outcome after cardiac surgery. Intensive insulin therapy with tight blood glucose control in surgical patients while in the ICU may reduce morbidity and mortality. Such outcome improvements would clearly provide benefits to patients, providers and payers. To date, there is scant research examining whether intensive insulin therapy for tight control of blood glucose in the perioperative period can alter outcomes for the non cardiac surgery population. The purpose of this study is to determine whether intensive insulin therapy for tight control of blood glucose in the perioperative period in non cardiac major surgery patients is associated with altered morbidity and mortality rates.

Condition or Disease	Intervention/Treatment	Phase
Hyperglycemia	Procedure: intensive glycemic control; Drug: conventional glycemic control	N/A

Detailed Description

Intensive insulin therapy to control blood glucose levels reduces morbidity and mortality in intensive care unit patients and in cardiac surgical patients but its role in patients undergoing non-emergent non-cardiac surgery is unknown. Benefits of glucose control may result from prevention of immune system dysfunction, reduction in systemic inflammation, and protection of endothelium and mitochondrial structure and function, all of which are known to be altered by high stress states such as that induced by surgical procedures.

In a prospective, randomized, controlled study of adult patients admitted to our operating suite for non-emergent non-cardiac surgery, we propose to correlate in-hospital morbidity and mortality with blood glucose levels of patients who are expected to have moderate to high levels of physiologic stress as a result of their pre-existing medical conditions or as a result of the proposed surgical procedure. Specifically, patients who are deemed to be American Society of Anesthesiologists Risk Classification 1-3 or higher, or patients undergoing intermediate and high risk procedures shall be considered to have moderate to high physiologic stress.

Determination of intermediate / high risk procedures shall be according to the American College of Cardiology / American Heart Association 2002 Guidelines for Perioperative Cardiovascular Evaluation for Noncardiac Surgery as outlined in Table 1.

Table 1. Cardiac Event Risk Stratification for Noncardiac Surgical Procedures High (Reported cardiac risk often >5%)

• Emergent major operations, particularly in the elderly

• Aortic and other major vascular surgery

• Peripheral vascular surgery

• Anticipated prolonged surgical procedures associated with large fluid shifts and/or blood loss Combined incidence of cardiac death and nonfatal myocardial infarction. Further preoperative cardiac testing is not generally required. Intermediate (Reported cardiac risk generally <5%)

• Intraperitoneal and intrathoracic surgery

• Carotid endarterectomy surgery

• Head and neck surgery

• Orthopedic surgery

• Prostate surgery Low (Reported cardiac risk generally <1%):

• Endoscopic procedures

• Superficial procedures

• Cataract surgery

• Breast surgery

Prior to entering the operating suite for surgery, patients will be randomly assigned to receive either intensive insulin treatment or conventional insulin treatment. Treatment assignment will be performed using sealed envelopes, and patients stratified according to Table 2.

TABLE 2. Baseline Characteristics of Patients. Variable Intention to Treat Group P Value Male sex (%) Age (Years) Type of Surgery

• Intracranial (%)

• Head & Neck (%)

• Thoracic (%)

• Vascular (%)

• Gastrointestinal (%)

• Urologic (%)

• Orthopedic (%)

• Gynecologic (%)

• Myocutaneous (%) History of Cancer (%) History of Organ Failure before Surgery (%) Organ Failure After Surgery (%) History of Diabetes (%)

• Treated with insulin

• Treated with oral diabetic agent, diet or both

Inclusion criteria:

• Patients scheduled for non emergent surgery under either general or regional anesthesia deemed to have moderate to high physiologic stress

• Male and female subjects over the age of 18 with or without a diagnosis of diabetes mellitus

• Patients must be able to provide informed consent

Exclusion criteria:

• Cognitively impaired

• Non-English or Spanish speaking with no relative present who is fluent in reading and comprehending English or Spanish.

• Female patients of child bearing age who have a positive pregnancy test on admission.

In all patients, whole blood hemoglobin A1C and glucose levels will be drawn prior to induction of anesthesia. Additional whole blood glucose levels will be drawn at the time of induction of anesthesia, at skin incision, hourly throughout the operation, at emergence from anesthesia, every hour up to three hours after the completion of surgery, and then once per day until the patient is discharged from the hospital.

In the intensive treatment group, continuous insulin infusion (50 IU of Novolin R [Novo Nordisk]) in 50mL of 0.9% saline via infusion pump will be started when the blood glucose level exceeds 110 mg/dL and will be adjusted to maintain the blood glucose level between 80 and 110 mg/dL. Adjustments will be made according to the University Hospital's ICU Adult Insulin Infusion Protocol. When the blood glucose level falls below 80 mg/dL, the insulin infusion will be tapered and discontinued. For patients going to the ICU after surgery, insulin infusions will be continued according to the University Hospital's ICU Adult Insulin Infusion Protocol under the direction of the ICU staff. For patients not being to the ICU after surgery, insulin infusions will be tapered to off after the final hourly blood glucose determination at three hours after the completion of surgery. The University Hospital's Blood Glucose Management Order Set for Medical and Surgical Patients will then be adopted for continued glucose management.

In the conventional treatment group, continuous insulin infusion will be started when the blood glucose level exceeds 200 mg/dL and will be adjusted to maintain the blood glucose level between 180 and 200 mg/dL. Adjustments will be made according to a modified ICU Adult Insulin Infusion Protocol. When the blood glucose level falls below 180mg/dL, the insulin infusion will be tapered and discontinued. For patients transferred to an ICU after surgery, insulin infusions will be continued according to the University Hospital's ICU Adult Insulin Infusion Protocol under the direction of the ICU staff. For patients not being transferred to an ICU after surgery, insulin infusions will be tapered to off after the final hourly blood glucose determination at three hours after the completion of surgery. The University Hospital's Blood Glucose Management Order Set for Medical and Surgical Patients will then be adopted for continued glucose management.

How will the study be analyzed?

At baseline, data on demographic and clinical characteristics of the patients (see Table 1) will be obtained. Blood will be systematically sampled and whole blood glucose levels determined as described above. All blood glucose values will be tabulated from baseline through end of study.

A research associate blinded to the treatment groups will determine morbidity and mortality by reviewing the patient's medical record upon discharge from the hospital and recording the occurrence of morbidity and mortality by the following criteria:

1. Post-operative surgical wound infection - a clinical condition requiring antibiotic treatment beyond the UH Surgical Infection Prevention (SIP) protocol and / or subsequent wound drainage / debridement

2. Systemic infection - presence of bacteremia or prolonged (i.e. greater than 10 days) use of antibiotics

3. Myocardial Injury - postoperative EKG changes that reveal new Q waves or S-T segment elevations greater than 1mm in any lead(s) or serum troponin levels that exceed….

4. Malignant arrhythmia - asystole, ventricular tachycardia or fibrillation requiring cardiopulmonary resuscitation, antiarrhythmia therapy, or defibrillator implantation

5. Respiratory Injury - mechanical ventilation for more than 48 hours, reintubation, or planned tracheostomy

6. Neurological Injury - focal brain injury with permanent functional deficit, irreversible encephalopathy

7. Renal Injury - a level of serum creatinine twice that present on admission to the hospital or acute renal failure requiring dialysis

8. Hepatic Injury - bilirubin level of >3mg per deciliter

9. Venous Thromboembolism - deposition of thrombus in peripheral or central veins as determined by Doppler ultrasonography, angiography or computed tomography.

Study Design

• Study Type: Interventional
• Actual Enrollment: 56 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: The Association Between Peri-Operative Hyperglycemia and Major Morbidity and Mortality
• Study Start Date: Jun 1, 2007
• Actual Primary Completion Date: Jan 1, 2009
• Actual Study Completion Date: Jan 1, 2009

Arms and Interventions

Arm	Intervention/Treatment
Experimental: intensive glycemic control In the intensive treatment group, continuous insulin infusion (50 IU of Novolin R [Novo Nordisk]) in 50ml of 0.9% saline via infusion pump will be started when the blood glucose level exceeds 110 mg / dL on two consecutive samples and will be adjusted to maintain the blood glucose level between 80 and 110 mg / dL. If the glucose level falls below 80 mg / dL, the insulin infusion will be tapered and discontinued.	Procedure: intensive glycemic control; intravenous insulin titrated every 30 minutes to serum glycemic level of 80-100mg/dl; Other Names: Novo Regular Insulin
Active Comparator: conventional glycemic control In this group if the subject's blood glucose level should exceed 200 mg/dL the subject will be treated with a continuous insulin infusion to maintain blood glucose levels between 180-200mg/dL	Drug: conventional glycemic control; Novo regular insulin administered when glucose level exceeded 200 mg/dl and titrated to maintain level between 180-200 mg/dl

Outcome Measures

Primary Outcome Measures

1. Wound Infection [7-10 days post op]

Secondary Outcome Measures

1. Hemodynamic Instability [0-48 hours post op]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 95 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Patients scheduled for non emergent surgery under either general or regional anesthesia deemed to have moderate to high physiologic stress

• Male and female subjects over the age of 18 with or without a diagnosis of diabetes mellitus

• Patients must be able to provide informed consent

Exclusion Criteria:

• Cognitively impaired

• Non-English or Spanish speaking with no relative present who is fluent in reading and comprehending English or Spanish.

• Female patients of child bearing age who have a positive pregnancy test on admission.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	University Hospital	Newark	New Jersey	United States	07107

Sponsors and Collaborators

• University of Medicine and Dentistry of New Jersey

Investigators

• Principal Investigator: J Jeffery Freda, MD, MBA, Rutgers, The State University of New Jersey

Study Documents (Full-Text)

None provided.

More Information

Publications

• Furnary AP, Gao G, Grunkemeier GL, Wu Y, Zerr KJ, Bookin SO, Floten HS, Starr A. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2003 May;125(5):1007-21.
• Ouattara A, Lecomte P, Le Manach Y, Landi M, Jacqueminet S, Platonov I, Bonnet N, Riou B, Coriat P. Poor intraoperative blood glucose control is associated with a worsened hospital outcome after cardiac surgery in diabetic patients. Anesthesiology. 2005 Oct;103(4):687-94.
• van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001 Nov 8;345(19):1359-67.

• Responsible Party: University of Medicine and Dentistry of New Jersey
• ClinicalTrials.gov Identifier: NCT00487162
• Other Study ID Numbers: 0120070093
• First Posted: Jun 15, 2007
• Last Update Posted: Nov 8, 2016
• Last Verified: Sep 1, 2016

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Keywords provided by University of Medicine and Dentistry of New Jersey: glycemic control, diabetes, obesity, comorbidities
• Additional relevant MeSH terms: Hyperglycemia; Insulin

Study Results

Participant Flow

Recruitment Details	enrollment period 6/07-3/09. potential subjects were recruited from the pre-operative admission unit and were screened if there ages were 18-90,undergoing general anesthesia for surgical procedures greater than 2 hours.
Pre-assignment Detail	Subjects were randomized to a specific study arm based on a computer generated randomization table. 49 participants are included in the baseline characteristic module because although 56 signed consent, some subjects withdrew the consent prior to study procedures and several withdrawn by attending anesthesiologist.

Arm/Group Title	Conventional Glycemic Control	Intensive Glycemic Control
Arm/Group Description	Subjects randomized to this study arm had their glucose levels monitored hourly and if the result was greater than 200mg/dL their anesthesia care provider was notified. The subject was treated as to thie care provider discretion.	In the intensive treatment group, continuous insulin infusion (50 IU of Novolin R [Novo Nordisk]) in 50ml of 0.9% saline via infusion pump will be started when the blood glucose level exceeds 110 mg / dL on two consecutive samples and will be adjusted to maintain the blood glucose level between 80 and 110 mg / dL. Adjustments will be made according to the University Hospital's ICU Adult Insulin Infusion Protocol - modified 10/1/07 (Appendix A). When the blood glucose level falls below 80 mg / dL, the insulin infusion will be tapered and discontinued. For patients going to the ICU after surgery, insulin infusions will be continued according to the University Hospital's ICU Adult Insulin Infusion Protocol under the direction of the ICU staff. For patients not being to the ICU after surgery, insulin infusions will be tapered to off after the final hourly blood glucose determination at three hours after the completion of surgery.
Period Title: Overall Study
STARTED	30	26
COMPLETED	28	21
NOT COMPLETED	2	5

Baseline Characteristics

Arm/Group Title	Conventional Glycemic Control	Intensive Glycemic Control	Total
Arm/Group Description	Subjects randomized to this study arm had their glucose levels monitored hourly and if the result was greater than 200 mg/dL their anesthesia care provider was notified. The subject was treated as to their care provider discretion.	In this treatment group, continuous insulin infusion (50 IU of Novolin R [Novo Nordisk]) in 50mL of 0.9% saline via infusion pump will be started when the blood glucose level exceeds 110 mg/dL and will be adjusted to maintain the blood glucose level between 80 and 110 mg/dL.	Total of all reporting groups
Overall Participants	28	21	49
Age (Count of Participants)
<=18 years	0 0%	0 0%	0 0%
Between 18 and 65 years	25 89.3%	20 95.2%	45 91.8%
>=65 years	3 10.7%	1 4.8%	4 8.2%
Sex: Female, Male (Count of Participants)
Female	12 42.9%	13 61.9%	25 51%
Male	16 57.1%	8 38.1%	24 49%

Outcome Measures

1. Primary Outcome

Title	Wound Infection
Time Frame	7-10 days post op

Outcome Measure Data

Analysis Population Description

no analysis was done as the study was terminated due to patient safety concerns

Arm/Group Title	Strict Glycemic Control	Conventional Glycemic Control
Arm/Group Description	strict glycemic control: intravenous insulin titrated every 30 minutes to serum glycemic level of 80-100mg/dl	conventional glycemic control: Novo regular insulin administered when glucose level exceeded 200 mg/dl and titrated to maintain level between 180-200 mg/dl
Measure Participants	0	0

2. Secondary Outcome

Title	Hemodynamic Instability
Time Frame	0-48 hours post op

Outcome Measure Data

Analysis Population Description

no analysis was done as the study was terminated due to patient safety concerns

Arm/Group Title	Strict Glycemic Control	Conventional Glycemic Control
Arm/Group Description	strict glycemic control: intravenous insulin titrated every 30 minutes to serum glycemic level of 80-100mg/dl	conventional glycemic control: Novo regular insulin administered when glucose level exceeded 200 mg/dl and titrated to maintain level between 180-200 mg/dl
Measure Participants	0	0

Adverse Events

Arm/Group Title	Conventional Glycemic Control		Intensive Glycemic Control
Arm/Group Description	Subjects randomized to this study arm had their glucose levels monitored hourly and if the result was greater than 200mg/dL their anesthesia care provider was notified. The subject was treated as to their care provider discretion.		Subjects randomized to this group had glucose levels monitored hourly and when >110mg/dL an insulin drip was initiated to maintain glucose levels between 80-110
All Cause Mortality
	Conventional Glycemic Control		Intensive Glycemic Control
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	/ (NaN)		/ (NaN)
Serious Adverse Events
	Conventional Glycemic Control		Intensive Glycemic Control
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/28 (0%)		0/21 (0%)
Other (Not Including Serious) Adverse Events
	Conventional Glycemic Control		Intensive Glycemic Control
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/28 (0%)		1/21 (4.8%)
Endocrine disorders
hypoglycemia	0/28 (0%)		1/21 (4.8%)

Limitations/Caveats

Study was terminated. No final conclusion drawn. A sentinel article was published in Feb 2009 issue of Anesthesiology which questioned the safety of intense insulin therapy/strict glycemic control.

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.